A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology Publication A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology CertaraJuly 13, 2010
Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis Publication Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients…CertaraJuly 1, 2010
What Does Clearance Mean? Knowledge Base What Does Clearance Mean? Drug clearance is an extremely important topic in the science of pharmacokinetics. Drug clearance defines…CertaraJune 13, 2010
Understanding Volume of Distribution BlogKnowledge Base Understanding Volume of Distribution Register for our July 10 webinar and discover fast, flexible, frictionless PK/PD workflows with Phoenix…CertaraJune 5, 2010
Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis Publication Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis Phenylbutyric acid (PBA), which is approved for treatment of urea cycle disorders (UCDs) as sodium…CertaraJune 1, 2010
What is Pharmacodynamics? Knowledge Base What is Pharmacodynamics? Starting with definitions is always helpful… so after defining pharmacokinetics, a definition for pharmacodynamics is…CertaraMay 24, 2010
What is Pharmacokinetics? Knowledge Base What is Pharmacokinetics? You might think this is a simple question, especially for an expert in pharmacokinetics. Well,…CertaraMay 16, 2010
Population Pharmacokinetic/Pharmacodynamic Model for a C.E.R.A. in Both ESA-naive and ESA-treated Chronic Kidney Disease Patients with Renal Anemia Publication Population Pharmacokinetic/Pharmacodynamic Model for a C.E.R.A. in Both ESA-naive and ESA-treated Chronic Kidney Disease Patients with Renal Anemia This study aimed to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model for C.E.R.A., a continuous erythropoietin…CertaraMay 1, 2010
Population Pharmacokinetics of Teduglutide Following Repeated Subcutaneous Administrations in Healthy Participants and in Patients with Short Bowel Syndrome and Crohn’s Disease Publication Population Pharmacokinetics of Teduglutide Following Repeated Subcutaneous Administrations in Healthy Participants and in Patients with Short Bowel Syndrome and Crohn’s Disease Teduglutide is a GLP-2 analog currently evaluated for the treatment of short bowel syndrome, Crohn's…CertaraJanuary 1, 2010
Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a Glucagon-like Peptide-2 Analog in Neonates and Infants with Short-bowel Syndrome Publication Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a Glucagon-like Peptide-2 Analog in Neonates and Infants with Short-bowel Syndrome Teduglutide, a synthetic glucagon-like peptide-2 (GLP-2) analog with activity relating to the regeneration, maintenance, and…CertaraDecember 1, 2009